Quris-AI

Quris-AI has developed a proprietary Bio-AI Clinical Prediction Platform that combines machine learning, generative AI, and "patients-on-a-chip" technology to predict the safety and efficacy of new drugs in humans. The company claims its approach can significantly reduce failed clinical trials by better predicting human responses before entering the clinic. As of early 2025, they are preparing for their first clinical testing with an AI-designed drug candidate. The platform has been validated through partnerships with major pharma companies such as Merck KGaA Darmstadt Germany. No public data yet on completed human trials.